UMN Pharma Of Japan Begins Phase II Trials On Bird Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
Japan's UMN Pharma has begun Phase II trials on its UMN-0501 avian flu vaccine, which the company expects to be able to produce within eight weeks of starting culturing procedures